Tonix Pharmaceuticals announced June 10 that its investigational reformulation of cyclobenzaprine, TNX-102 SL, received IND clearance from the FDA for the treatment of post-traumatic stress disorder. The news comes about a month after the company said that TNX-102 SL's pivotal trial for the treatment of fibromyalgia completed enrollment.
Cook Medical announced the launch of what it said is Canada's first drug-coated stent for the treatment of peripheral arterial disease in the superficial femoral artery on June 5 at the Interventional Radiology Association meeting in Montreal.
The blood-brain barrier is the body's way of keeping harmful substances away from the brain, but it's also a daunting obstacle for drug delivery experts looking to send treatments to the organ. Now, researchers at the Mayo Clinic have developed a synthetic peptide carrier to shuttle small molecules past the barrier and into the brain.
Only a few weeks ago, there was talk of a biotech stock slump, but now some of those same companies in vogue again, at least in the popular press.
The success (or failure) of still-unproven biotech BioDeliverySciences will depend in great part on its buccal film for opioid dependence, Bunavail. The candidate is barreling toward its June 6 PDUFA date.
Researchers in Singapore have developed a nanotech solution that could provide months of treatment in a single application.
Like a molecular swiss army knife, a new type of technique that engineers have dubbed "quadrapeutics" offers a four-in-one cancer treatment to blast tumors into submission, and a preclinical study showed that it was 17 times more effective than traditional chemotherapy.
FDA's May 28 approval of Natesto, the first nasally delivered testosterone gel for hypogonadism, came just in time for Canada's Trimel Pharmaceuticals, which had just $18 million left on hand at the beginning of the year.
With all the innovation in nano-sized delivery vehicles, the creative terms for the small particles have run the gamut from nanonecklaces to nanovolcanoes. And scientists from North Carolina State University, following suit, have dubbed their new design for delivering cancer drugs a "nanodaisy," due to a flowerlike petal structure on its surface.
France's Stentys anticipates a CE mark for its sirolimus-eluting stent as soon as the second half of 2014 due to the results of its three clinical trials released May 27 in a late-breaking session of the EuroPCR conference in Paris.
The U.K.'s PolyTherics, which just this week merged with Antitope to pool their resources in R&D, announced that it would also collaborate with Canadian company Alpha Cancer Technologies, which has a drug delivery platform called alpha fetoprotein designed to enhance chemotherapy.
Mannkind officials signaled FDA approval of its inhaled diabetes Afrezza Inhalation Powder is likely at their May 22 shareholder meeting.
Biotech Inovio revealed that all the mice that received its monoclonal antibody targeting chikungunya virus were protected from the disease, raising hopes that the first drug for the condition could be on the horizon.
In the interest of designing new nano-sized vehicles for cardiovascular drugs, Swiss researchers have developed an X-ray technique for visualizing blood vessels that have been constricted by atherosclerosis.
Mobility is an important function of any drug-delivering robot--even a well-designed machine that ultimately can't get where it's needed serves little to no purpose. To this end, researchers have developed a wide range of innovative devices from microrockets to DNA propellers to sperm-driven robots.
Phosphagenics' TPM/Oxycodone topical patch to combat neuropathic pain in large companion animals relieved all racehorses within two days in an initial study, the company said May 21.
Glioblastoma multiforme, the most common and one of the most aggressive forms of brain cancer, is notoriously difficult to treat. Now, researchers have developed a novel method of dealing with the disease: They're infecting the tumor with herpesvirus, shuttled into the brain in stem cells.
Insmed's Phase II trial of Arikayce, or inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial lung infections, did not meet its primary endpoint, but new data released May 20 from the 84-day open-label extension show that patients receiving the compound showed significant improvement, the company said.
Reckitt Benckiser Pharmaceuticals announced May 19 that it is codeveloping what would be the first nasally administered naloxone-based therapy to treat emergency cases of opioid overdose from heroin or prescription painkillers.
At the American Society for Microbiology's annual meeting this week, a team of researchers from the University of California, Davis, demonstrated a study showing that silicon nanoparticles they designed could penetrate the blood-brain barrier.